Lexicon's sotagliflozin passes third Phase III diabetes test

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) said sotagliflozin (SAR439954) met the primary endpoint in the Phase III inTandem3 trial to treat Type I diabetes. The company said sotagliflozin was superior to placebo in the proportion of patients with an HbA1c of less than 7% at week 24 and without episodes of severe hypoglycemia or diabetic ketoacidosis (DKA).

Lexicon said sotagliflozin led to similar rates of severe hypoglycemia compared with placebo (3% vs. 2.4%), although there was a higher rate of DKA with sotagliflozin vs. placebo (3% vs. 0.6%). The company plans to publish full data in a peer-reviewed journal...